Recent studies have shown that doxorubicin induces NF-κB through interleukin-8 (IL-8) [42], whereas p53 inactivation is associated with the overexpression of MDM2/MDM4 in AML cell lines [43]. The gene discussed is TP53; the disease is acute myeloid leukemia.